|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Completes Acquisition of IDM Pharma, Inc. (IDMI)
6/25/2009
NEW YORK--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) today announced the completion of its acquisition of IDM Pharma, Inc. (“IDM”, NASDAQ: IDMI) for US$2.64 per share in cash, through a short-form merger of Jade Subsidiary Corporation (“Jade”), a wholly owned subsidiary of Takeda America Holdings, Inc., which is a wholly owned subsidiary of Takeda, into IDM. With the consummation of the merger, IDM has become a wholly owned subsidiary of Takeda America Holdings, Inc. This acquisition adds MEPACT® (mifamurtide), a novel therapy indicated for the treatment of osteosarcoma, to the Takeda oncology portfolio in Europe.
|
|
|
|
|
|
|
|
|
|
|
|